Literature DB >> 21106364

Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma.

Stefania Rossi1, Pietro Luigi Poliani, Manuela Cominelli, Andrea Bozzato, Raffaella Vescovi, Eugenio Monti, Alessandro Fanzani.   

Abstract

Caveolins consist of three different membrane scaffolding proteins that play a variety of processes in different tissues. In skeletal muscle caveolins are differentially distributed, with Caveolin 1 (Cav-1) being uniquely expressed in satellite cells and Caveolin 3 (Cav-3) in mature myofibers. Rhabdomyosarcoma (RMS) represents the most common childhood soft-tissue sarcoma arising from mesenchimal precursors which fail to undergo proper commitment to muscle lineage. Cav-3 has been proposed as a marker of RMS with a high degree of differentiation, while biological significance of Cav-1 expression in RMS is still a matter of debate. In the present study we show that Cav-1 is predominantly expressed in the embryonal RMS histotype, as further confirmed by transcript and protein analysis in different in vitro human RMS cell lines. Immature cell phenotype of human embryonal RD line, carrying spontaneous activating RAS mutations, was significantly associated to ERK MAPK signalling pathway and featured by high Cav-1 levels, whereas pharmacological attenuation of the ERK pathway, improving cell differentiation, lead to Cav-1 down-regulation. Overall, these data place Cav-1 as a valuable marker of diagnosis for RMS characterised by low degree of differentiation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106364     DOI: 10.1016/j.ejca.2010.10.018

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  10 in total

1.  Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Nicola Chiarelli; Marina Colombi; Stefania Mitola; Roberto Ronca; Luca Madaro; Marina Bouche; Pietro L Poliani; Marika Vezzoli; Francesca Longhena; Eugenio Monti; Barbara Salani; Davide Maggi; Charles Keller; Alessandro Fanzani
Journal:  Lab Invest       Date:  2015-03-30       Impact factor: 5.662

Review 2.  Caveolin-1 in sarcomas: friend or foe?

Authors:  Miguel Sáinz-Jaspeado; Juan Martin-Liberal; Laura Lagares-Tena; Silvia Mateo-Lozano; Xavier Garcia del Muro; Oscar M Tirado
Journal:  Oncotarget       Date:  2011-04

3.  Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders.

Authors:  Kamel Mamchaoui; Capucine Trollet; Anne Bigot; Elisa Negroni; Soraya Chaouch; Annie Wolff; Prashanth K Kandalla; Solenne Marie; James Di Santo; Jean Lacau St Guily; Francesco Muntoni; Jihee Kim; Susanne Philippi; Simone Spuler; Nicolas Levy; Sergiu C Blumen; Thomas Voit; Woodring E Wright; Ahmed Aamiri; Gillian Butler-Browne; Vincent Mouly
Journal:  Skelet Muscle       Date:  2011-11-01       Impact factor: 4.912

4.  MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.

Authors:  Fiorella Faggi; Silvia Codenotti; Pietro Luigi Poliani; Manuela Cominelli; Nicola Chiarelli; Marina Colombi; Marika Vezzoli; Eugenio Monti; Federica Bono; Giovanni Tulipano; Chiara Fiorentini; Alessandra Zanola; Harriet P Lo; Robert G Parton; Charles Keller; Alessandro Fanzani
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

5.  Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.

Authors:  Lee Campbell; Ghaith Al-Jayyoussi; Robert Gutteridge; Nigel Gumbleton; Rosie Griffiths; Simon Gumbleton; Mathew W Smith; David F R Griffiths; Mark Gumbleton
Journal:  J Transl Med       Date:  2013-10-11       Impact factor: 5.531

Review 6.  Caveolins in rhabdomyosarcoma.

Authors:  Stefania Rossi; Pietro Luigi Poliani; Cristina Missale; Eugenio Monti; Alessandro Fanzani
Journal:  J Cell Mol Med       Date:  2011-12       Impact factor: 5.310

7.  Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth.

Authors:  Juan Huertas-Martínez; Santiago Rello-Varona; David Herrero-Martín; Ignasi Barrau; Silvia García-Monclús; Miguel Sáinz-Jaspeado; Laura Lagares-Tena; Yaiza Núñez-Álvarez; Silvia Mateo-Lozano; Jaume Mora; Josep Roma; Nuria Toran; Sebastian Moran; Roser López-Alemany; Soledad Gallego; Manel Esteller; Miguel A Peinado; Xavier García Del Muro; Oscar M Tirado
Journal:  Oncotarget       Date:  2014-10-30

8.  Caveolin-1 is essential in the differentiation of human adipose-derived stem cells into hepatocyte-like cells via an MAPK pathway-dependent mechanism.

Authors:  Xin Guan; Nan Wang; Fenggong Cui; Yang Liu; Peng Liu; Jingyuan Zhao; Chao Han; Xiaoyan Li; Zhiqian Leng; Ying Li; Xiaofei Ji; Wei Zou; Jing Liu
Journal:  Mol Med Rep       Date:  2015-12-30       Impact factor: 2.952

9.  Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.

Authors:  Daryoush Saeed-Vafa; Douglas C Marchion; Susan M McCarthy; Ardeshir Hakam; Alexis Lopez; Robert M Wenham; Sachin M Apte; Dung-Tsa Chen; Anthony M Magliocco; Johnathan M Lancaster; Brett M Reid; Jennifer B Permuth
Journal:  PLoS One       Date:  2021-11-23       Impact factor: 3.240

10.  Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Stefania Mitola; Guglielmo Sorci; Francesca Riuzzi; Rosario Donato; Silvia Codenotti; Pietro Luigi Poliani; Manuela Cominelli; Raffaella Vescovi; Stefania Rossi; Stefano Calza; Marina Colombi; Fabio Penna; Paola Costelli; Ilaria Perini; Maurilio Sampaolesi; Eugenio Monti; Alessandro Fanzani
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.